Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Immutep stock

Own Immutep stock in just a few minutes.

Immutep Limited is a biotechnology business based in the US. Immutep shares (IMMP) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Immutep

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IMMP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Immutep share price

Use our graph to track the performance of IMMP stocks over time.

Immutep shares at a glance

Information last updated 2021-04-29.
52-week range$0.91 - $3.95
50-day moving average $3.14
200-day moving average $2.76
Wall St. target price$7.01
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.40

Buy Immutep shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Immutep stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immutep financials

Revenue TTM $6.4 million
Gross profit TTM $-6,656,699
Return on assets TTM -20%
Return on equity TTM -61.68%
Profit margin 0%
Book value $0.94
Market capitalisation $222.6 million

TTM: trailing 12 months

Shorting Immutep shares

There are currently 118,758 Immutep shares held short by investors – that's known as Immutep's "short interest". This figure is 64.7% down from 336,236 last month.

There are a few different ways that this level of interest in shorting Immutep shares can be evaluated.

Immutep's "short interest ratio" (SIR)

Immutep's "short interest ratio" (SIR) is the quantity of Immutep shares currently shorted divided by the average quantity of Immutep shares traded daily (recently around 5.9 million). Immutep's SIR currently stands at 0.02. In other words for every 100,000 Immutep shares traded daily on the market, roughly 20 shares are currently held short.

However Immutep's short interest can also be evaluated against the total number of Immutep shares, or, against the total number of tradable Immutep shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immutep's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Immutep shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Immutep shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immutep.

Find out more about how you can short Immutep stock.

Immutep share dividends

We're not expecting Immutep to pay a dividend over the next 12 months.

Have Immutep's shares ever split?

Immutep's shares were split on a 1:10 basis on 6 November 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Immutep shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Immutep shares which in turn could have impacted Immutep's share price.

Immutep share price volatility

Over the last 12 months, Immutep's shares have ranged in value from as little as $0.91 up to $3.95. A popular way to gauge a stock's volatility is its "beta".

IMMP.US volatility(beta: 1.32)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immutep's is 1.3206. This would suggest that Immutep's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Immutep overview

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc. , INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017.

Frequently asked questions

What percentage of Immutep is owned by institutions?
Currently 0.372% of Immutep shares are held by institutions.
When does the fiscal year end for Immutep?
Immutep's fiscal year ends in June.
Where is Immutep based?
Immutep's address is: 95 Pitt Street, Sydney, NSW, Australia, 2000
What is Immutep's ISIN number?
Immutep's international securities identification number is: US45257L1089
What is Immutep's CUSIP number?
Immutep's Committee on Uniform Securities Identification Procedures number is: 45257L108

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site